Micronized 17B-estradiol
Phase 2/3Completed 1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerosis
Conditions
Atherosclerosis, Postmenopause
Trial Timeline
Apr 1, 1994 → Nov 1, 1998
NCT ID
NCT00115024About Micronized 17B-estradiol
Micronized 17B-estradiol is a phase 2/3 stage product being developed by Johnson & Johnson for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00115024. Target conditions include Atherosclerosis, Postmenopause.
What happened to similar drugs?
8 of 20 similar drugs in Atherosclerosis were approved
Approved (8) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00115024 | Phase 2/3 | Completed |
Competing Products
20 competing products in Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 47 |
| Olmesartan medoxomil + Placebo | Daiichi Sankyo | Phase 3 | 40 |
| Pactimibe sulfate | Daiichi Sankyo | Phase 2/3 | 30 |
| Pactimibe | Daiichi Sankyo | Phase 2 | 35 |
| Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin | Daiichi Sankyo | Phase 3 | 47 |
| Rosuvastatin + placebo + aspirin + placebo | AstraZeneca | Approved | 43 |
| Rosuvastatin + Placebo | AstraZeneca | Approved | 35 |
| rosuvastatin + placebo | AstraZeneca | Phase 1 | 29 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 1 | 29 |
| Rosuvastatin + Atorvastatin | AstraZeneca | Phase 3 | 40 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 40 |
| Rosuvastatin (5mg,10mg,20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 39 |
| Vorapaxar + Placebo | Merck | Phase 3 | 40 |
| Vorapaxar + Placebo + Aspirin + Clopidogrel | Merck | Phase 2 | 35 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 43 |
| lovastatin | Merck | Phase 2/3 | 38 |
| Ezetimibe + Placebo | Merck | Approved | 43 |
| Vorapaxar + Placebo | Merck | Phase 3 | 32 |
| Niaspan | Merck | Pre-clinical | 22 |
| MK0633 | Merck | Phase 2 | 35 |